June 2016

New Product - Jetrea

Jetrea (ocriplasmin (ryp)) is a recombinant truncated form of human plasmin produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin has a proteolytic activity against protein components of the vitreous body and the vitreoretinal interface (e.g. laminin, fibronectin and collagen), and aims to dissolve the protein matrix responsible for the abnormal vitreomacular adhesion. Jetrea is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with a macular hole of diameter less than or equal to 400 microns. Jetrea is contraindicated in those with active or suspected ocular or periocular infections. Jetrea is available as a single use glass vial of concentrated solution for injection containing 0.5 mg of ocriplasmin (ryp) in a 0.2 mL citric-buffered solution in carton of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au